Paclitaxel treatment induced the expression of colony-stimulating factor (CSF)-1 in tissues from chemoresistant breast cancer xenografts, which stimulated the recruitment of TAMs, while CSF-1 signaling inhibition reduced TAM recruitment and restored paclitaxel antitumoral effects [62]. The gene discussed is CSF1; the disease is breast cancer.